Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Linköping Sweden.
Department of Medical and Health Sciences Division of Drug Research Linköping University Linköping Sweden.
Pharmacol Res Perspect. 2018 Jul 5;6(4):e00419. doi: 10.1002/prp2.419. eCollection 2018 Jul.
Tramadol is a complex drug, being metabolized by polymorphic enzymes and administered as a racemate with the (+)- and (-)-enantiomers of the parent compound and metabolites showing different pharmacological effects. The study aimed to simultaneously determine the enantiomer concentrations of tramadol, -desmethyltramadol, -desmethyltramadol, and -didesmethyltramadol following a single dose, and elucidate if enantioselective pharmacokinetics is associated with the time following drug intake and if interindividual differences may be genetically explained. Nineteen healthy volunteers were orally administered either 50 or 100 mg tramadol, whereupon blood samples were drawn at 17 occasions. Enantiomer concentrations in whole blood were measured by LC-MS/MS and the , and genotype were determined, using the xTAG CYP2D6 Kit, pyrosequencing and real-time PCR, respectively. A positive correlation between the (+)/(-)-enantiomer ratio and time following drug administration was shown for all four enantiomer pairs. The largest increase in enantiomer ratio was observed for -desmethyltramadol in CYP2D6 extensive and intermediate metabolizers, rising from about two to almost seven during 24 hours following drug intake. CYP2D6 poor metabolizers showed metabolic profiles markedly different from the ones of intermediate and extensive metabolizers, with large area under the concentration curves (AUCs) of the -desmethyltramadol enantiomers and low corresponding values of the -desmethyltramadol and -didesmethyltramadol enantiomers, especially of the (+)-enantiomers. Homozygosity of and indicated a reduced enzyme function, although further studies are required to confirm it. In conclusion, the increase in enantiomer ratios over time might possibly be used to distinguish a recent tramadol intake from a past one. It also implies that, even though (+)--desmethyltramadol is regarded the enantiomer most potent in causing adverse effects, one should not investigate the (+)/(-)-enantiomer ratio of -desmethyltramadol in relation to side effects without consideration for the time that has passed since drug intake.
曲马多是一种复杂的药物,其代谢由多态酶进行,作为外消旋体给药,母体化合物的 (+)-和 (-)-对映异构体以及代谢物表现出不同的药理作用。本研究旨在单次给药后同时测定曲马多、-去甲基曲马多、-去甲基曲马多和-didesmethyltramadol 的对映体浓度,并阐明对映选择性药代动力学是否与药物摄入后的时间有关,以及个体间差异是否可以从遗传上解释。19 名健康志愿者分别口服 50 或 100mg 曲马多,随后在 17 个时间点抽取血样。采用 LC-MS/MS 测定全血中对映体浓度,使用 xTAG CYP2D6 试剂盒、焦磷酸测序和实时 PCR 分别测定 和 基因型。所有四对对映体均显示 (+)/(-) 对映体比值与药物摄入后时间呈正相关。在 CYP2D6 广泛和中度代谢者中,-去甲基曲马多的对映体比值增加最大,从药物摄入后 24 小时内的约 2 增加到近 7。CYP2D6 弱代谢者的代谢谱与中效和强效代谢者明显不同,-去甲基曲马多对映体的 AUC 较大,而相应的 -desmethyltramadol 和 -didesmethyltramadol 对映体的 AUC 较低,尤其是 (+)-对映体。 和 的纯合性表明酶功能降低,尽管需要进一步研究来证实这一点。总之,随着时间的推移,对映体比值的增加可能用于区分最近的曲马多摄入和过去的摄入。这也意味着,即使 (+)--去甲基曲马多被认为是引起不良反应最有效的对映体,但在不考虑药物摄入后时间的情况下,不应仅根据 -去甲基曲马多的 (+)/(-) 对映体比值来研究不良反应。